TCRX,TScan Therapeutics, Inc. | Healthcare

Healthcare

TCRX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

TScan Therapeutics, Inc.TCRX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors.

In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Latest News >

US blocks $63 million in funds of global terrorist groups in 2019: Report

Dec 31, 2020

According to the report, in 2019 the US blocked USD 63 million in funds of nearly 70 designated terrorist organisations, with the highest being USD 3.9 million of the al-Qaeda group. While the total blocked funds in 2018 was USD 46 million, that of the al-Qaeda was USD 6.4 million that year.

Recovery should start in Q2 with vaccine and fiscal stimulus in global markets: BofA Global

Dec 31, 2020

The paradox of the last quarter has been that global equity markets, in fact all global risk assets, have been reaching higher and higher but the economies in almost all countries is healing very gradually, in some cases even affected by a third and a fourth surge of the infection. How to marry this paradox and what lies in store for 2021? To 'answer all these, CNBC-TV18’s Latha Venkatesh spoke to Ethan Harris, head of Global Economics, BofA Global Research.

Trump extends visa ban, health coverage policy advances

Dec 31, 2020

The twin developments on the final day of 2020 encapsulated how Trump has made US immigration policy more restrictive without support from Congress.

India set to begin its two-year tenure as non-permanent member of UNSC

Jan 1, 2021

United Nations: India, which has been at the forefront of the years-long efforts to reform the UN Security Council, will begin its two-year tenure as a non-permanent member of the powerful organ of the world body on Friday. India will sit in the 15-nation United Nations Security Council (UNSC) for the 2021-22 term as a non-permanent member - the eighth time that the country has had a seat on the powerful horseshoe table.